^
No biomarker
Melanoma
BNT111
Sensitive: A1 - Approval
BioNTech Press Release - 1 week
BRAF mutation
Melanoma
PD1 inhibitor + BRAF inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
BRAF mutation
Melanoma
PD1 inhibitor + BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
NLRP3 mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Aging (Albany NY) - 2 weeks
GDF15-L
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
PD-L1-H + CXCL10-H + TNFA-H
Melanoma
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
IFIT3 overexpression
Cutaneous Melanoma
dasatinib
Sensitive: C3 – Early Trials
Int Immunopharmacol - 2 weeks
IFIT1 overexpression
Cutaneous Melanoma
dasatinib
Sensitive: C3 – Early Trials
Int Immunopharmacol - 2 weeks
No biomarker
BCC
cemiplimab
Sensitive: A1 - Approval
Sanofi Press Release - 4 weeks
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
No biomarker
BCC
vismodegib
Sensitive: A1 - Approval
No biomarker
Merkel Cell Carcinoma
avelumab
Sensitive: A1 - Approval
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
BCC
imiquimod
Sensitive: A1 - Approval
No biomarker
Melanoma
ipilimumab
Sensitive: A1 - Approval
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
No biomarker
Melanoma
trametinib
Resistant: A1 - Approval
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
No biomarker
BCC
sonidegib
Sensitive: A1 - Approval
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive: A1 - Approval
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Melanoma
aldesleukin
Sensitive: A1 - Approval
No biomarker
BCC
celecoxib
Resistant: A2 - Guideline
No biomarker
Cutaneous Melanoma
TC
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
TC
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
EP
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
ipilimumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
temozolomide
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
trametinib
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
BRAF mutation
Melanoma
dabrafenib + granisetron intravenous
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
NRAS mutation
Melanoma
binimetinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
cisplatin
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
carboplatin
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
topotecan
Sensitive: A2 - Guideline
NTRK1 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
ROS1 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
KIT exon 11 mutation
Melanoma
sunitinib
Sensitive: A2 - Guideline
KIT exon 11 mutation
Melanoma
nilotinib
Sensitive: A2 - Guideline
KIT exon 13 mutation
Melanoma
sunitinib
Sensitive: A2 - Guideline
BRAF V600K
Melanoma
dabrafenib
Sensitive: A2 - Guideline
TMB-H
Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ROS1 fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
NTRK3 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
KIT exon 13 mutation
Melanoma
nilotinib
Sensitive: A2 - Guideline
BRAF fusion
Melanoma
sorafenib
Sensitive: A2 - Guideline
ALK fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
ALK fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
talimogene laherparepvec
Sensitive: A2 - Guideline